Free Trial
NASDAQ:ETON

Eton Pharmaceuticals Q4 2024 Earnings Report

Eton Pharmaceuticals logo
$30.15 -0.23 (-0.76%)
Closing price 04:00 PM Eastern
Extended Trading
$29.88 -0.27 (-0.91%)
As of 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eton Pharmaceuticals EPS Results

Actual EPS
-$0.02
Consensus EPS
-$0.02
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Eton Pharmaceuticals Revenue Results

Actual Revenue
$11.65 million
Expected Revenue
$10.53 million
Beat/Miss
Beat by +$1.12 million
YoY Revenue Growth
N/A

Eton Pharmaceuticals Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Tuesday, March 18, 2025
Conference Call Time
10:00AM ET

Upcoming Earnings

Eton Pharmaceuticals' Q1 2026 earnings is estimated for Tuesday, May 12, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, May 14, 2026 at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Eton Pharmaceuticals Earnings Headlines

Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors.tc pixel
Eton Pharmaceuticals (NASDAQ:ETON) Trading 13.3% Higher - Here's Why
See More Eton Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Eton Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eton Pharmaceuticals and other key companies, straight to your email.

About Eton Pharmaceuticals

Eton Pharmaceuticals (NASDAQ:ETON) is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis. Eton gained U.S. Food and Drug Administration approval for several abbreviated new drug applications (ANDAs) and new drug applications (NDAs), enabling it to bring both generic and specialty branded medicines to market. Its development pipeline features additional hormone replacement therapies and other complex dosage forms intended to broaden its reach in endocrine and rare disease markets.

Eton Pharmaceuticals serves patients and healthcare providers across the United States through strategic partnerships with wholesalers, specialty pharmacies and healthcare institutions. The company employs a network of contract manufacturing organizations to ensure product quality and supply chain efficiency. With a focus on regulatory compliance, timely product launches and niche market development, Eton continues to pursue opportunities that align with its mission of improving care for patients with limited treatment options.

View Eton Pharmaceuticals Profile